🇺🇸 zidovudine+lamivudine+lopinavir/ritonavir in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Abortion Spontaneous — 1 report (50%)
- Maternal Exposure During Pregnancy — 1 report (50%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is zidovudine+lamivudine+lopinavir/ritonavir approved in United States?
zidovudine+lamivudine+lopinavir/ritonavir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for zidovudine+lamivudine+lopinavir/ritonavir in United States?
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the originator. The local marketing authorisation holder may differ — check the official source linked above.